Citius Pharmaceuticals (CTXR) - Quarterly EPS earnings growth

Official company branding of Citius Pharmaceuticals Inc. (CTXR)

Citius Pharmaceuticals is expanding its presence in the intensive care and oncology segments by attracting the hospital sector. The Mino-Lok product enables the treatment of infections without removing catheters, thereby reducing clinic costs. Simultaneously, the company is implementing energy-efficient technologies and the safe disposal of chemicals. This chart on GURU.Markets reflects the growth rates of quarterly net income per share, where this metric stands at 57.30.

Citius Pharmaceuticals, Inc. (CTXR) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Citius Pharmaceuticals

- market value and analyst target forecast:
Price Chart citiuspharma.com|CTXR - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Citius Pharma|CTXR - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Citius Pharmaceuticals|CTXR - Total Stockholders' Equity|Market Value to Book Value Ratio citiuspharma.com|CTXR - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Citius Pharmaceuticals|CTXR - Long-Term Liabilities to Capital|Short-Term Debt to Capital citiuspharma.com|CTXR - Company Total Indebtedness|Debt to Book Value Citius Pharma|CTXR - Long-Term Debt|Company Current Liabilities Citius Pharmaceuticals|Quick Liquidity Indicator citiuspharma.com
- earnings and market multiples details:
CTXR - Profit After Payment of Taxes|Projected Future Earnings Citius Pharmaceuticals|CTXR - Company Value to Net Income|Forward P/E Multiple citiuspharma.com|CTXR - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Pharma|CTXR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Citius Pharmaceuticals|CTXR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months citiuspharma.com|CTXR - Earnings per share trend in current year|Expected earnings per share growth for next year Citius Pharmaceuticals
- sales volume and revenue indicators:
CTXR - Company Total Revenue|Projected Sales Volume citiuspharma.com|CTXR - Market Cap to Revenue|Forward P/S Multiple Citius Pharma
Fundamental company analysis:Citius Pharmaceuticals Inc., CTXR
Manufactured product of Citius Pharmaceuticals

Citius Pharmaceuticals (CTXR) is investing in the development of biodegradable gels and protein synthesis for the therapy of critical conditions, which necessitates strict control over financial efficiency. The quarterly earnings per share (EPS) growth trend measures the rate of change in net income, allowing investors to determine via the current quarterly EPS growth level whether fundamental successes justify the market value or if the asset is overvalued.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com